(Q35871850)

10 August 2017

1 reference

title

Evaluation and review of pharmacoeconomic models (English)

1 reference

10 August 2017

1

Joel W Hay

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1867-1880

1 reference

Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Modelling in economic evaluation: an unavoidable fact of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Econometric issues in modeling the costs of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

An introduction to Markov modelling for economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

A utility-theoretic model for QALYs and willingness to pay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

The friction cost method for measuring indirect costs of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Modeling choice behavior for new pharmaceutical products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Theoretical arguments for the discounting of health consequences: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Discounting for health effects in cost-benefit and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Data collection methods in prospective economic evaluations: how accurate are the results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Estimating endogenous treatment effects in retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Why Bayesian analysis hasn't caught on in healthcare decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Resampling and multiplicity in cost-effectiveness inference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Economic modeling and sensitivity analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Development and validation of a grading system for the quality of cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

The economic impact of the tacrine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

The journal's policy on cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Cost Effectiveness Analysis Applied to the Treatment of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

The relationship between cost-effectiveness analysis and cost-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

The friction cost method: A comment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

Guidelines for the clinical and economic evaluation of health care technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1867

10.1517/14656566.5.9.1867

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference